Table 7 Distribution of OTSCC immunohistochemical prognostic biomarkers studies according to countries
From: Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis
Number of studies (HR and CI were reported in the study for at least one survival endpoint) | |||||
|---|---|---|---|---|---|
Country | p53 | Ki-67 | p16 | VEGFs | Cyclin D1 |
Japan | 4 (2)a | 4 (2) | 2 (1)a | 5 (3)a | 5 (0) |
USA | 4 (0) | 1 (1) | 2 (1)a | – | – |
India | 3 (2)a | – | 4 (2)b | – | 2 (1)a |
China | 2 (0) | – | 1 (0) | 1 (1)a | 1 (0) |
Korea | 1 (0) | 1 (1) | – | 3 (0) | – |
Australia | 1 (1)a | 1 (1)a | 2 (2)b | – | 1 (1)a |
Finland | 1 (0) | 1 (1)a | – | – | – |
Iran | – | – | – | – | – |
Norway | 1 (0) | 1 (0) | – | – | – |
Sweden | 1 (1) | 1 (0) | 1 (0) | – | – |
Tunisia | 1 (0) | 1 (0) | – | – | – |
Turkey | 1 (0) | – | – | – | – |
Brazil | – | 2 (0) | – | – | 1 (0) |
Czech | – | – | 1 (0) | 1 (1)a | – |
Spain | – | – | 1 (0) | – | – |
USA & China | – | 1 (1)a | – | – | – |
Finland & Israel | – | 1 (1) | – | – | – |
Total number of studies | 20 | 15 | 14 | 10 | 10 |
